Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 29INDUSTRY 29OTHER_GOV 3FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 46Neoplasms 36Colorectal Neoplasms 36Lung Neoplasms 21Breast Neoplasms 13Colonic Polyps 11Colonic Neoplasms 11Rare Diseases 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 7Pulmonary Disease, Chronic Obstructive 6Neoplasm Metastasis 6Heart Failure 6Head and Neck Neoplasms 6Ovarian Neoplasms 5Motor Activity 5Liver Neoplasms 5Fibrosis 5Carcinoma, Squamous Cell 5Barrett Esophagus 5Adenoma 5Urinary Bladder Neoplasms 4Neoplasms by Site 4Mental Disorders 4Lymphoma 4Lung Diseases 4Leukemia 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Urinary Incontinence 3

Interventions

Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Interventional × Gastrointestinal Diseases × Clear all
NCT00004941 2015-03-25

Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

FDA Office of Orphan Products Development

Phase 3 Completed
94 enrolled
Gastrointestinal

Crohn Disease, Gastrointestinal Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡